TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9679581
Drug: UFT combined
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT combined with endocrine therapy for prostate cancer (10 patients)
Study: 2529028
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of HPR
Study: 2529028
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of HPR
Study: 2529028
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of HPR
Study: 1100225
Drug: NSC-122819 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSC-122819 (50 mg/m2/dose iv twice weekly for 4 weeks)
Study: 1100225
Drug: NSC-141540 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSC-141540 (75 mg/m2/dose iv twice weekly for 4 weeks)
Study: 23598288
Drug: Plasmalyte infusion
Normalized name: Plasmalyte A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmalyte infusion
Study: 11181464
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg/d
Study: 9835978
Drug: Continuous injection
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous injection (CA) group, n = 21
Study: 8129127
Drug: Tonsillar infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsillar infiltration with 0.25% bupivacaine administered after both tonsils had been surgically removed (n = 12)
Study: 2916912
Drug: Usual athletic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual athletic and daily physical activities (Control group).
Study: 4901344
Drug: Trimethoprim 320
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim 320 mg and Sulphamethoxazole 1,600 mg a day
Study: 4901344
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 g a day
Study: 19253204
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg q.d. and 50 mg b.i.d.
Study: 16633143
Drug: Fluvoxamine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (150 mg/d)
Study: 15283825
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol (20‐25 mg x kg(‐1)) preoperatively
Study: 15283825
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol (20‐25 mg x kg(‐1)) postoperatively
Study: 8386917
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nedocromil sodium four times daily for 12 weeks
Study: 3122518
Drug: Mannitol administered
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol administered 30 min prior to bypass
Study: 31977698
Drug: Submandibular anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submandibular anesthesia through catheter perfusion, lingual nerve block, and subcutaneous infiltration anesthesia
Study: 31977698
Drug: Lingual nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingual nerve block and subcutaneous infiltration anesthesia
Study: 30132686
Drug: Pediatric Prolonged-Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric Prolonged-Release Melatonin (PedPRM) 2/5 mg nightly for 39 weeks
Study: 24198051
Drug: Atorvastatin (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (5-10 mg for 3 months)
Study: 24198051
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg for 3 months)
Study: 22510898
Drug: Autologous platelet‐leukocyte‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet‐leukocyte‐enriched plasma spray
Study: 20149066
Drug: Experienced Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experienced Community Oral Health Workers (COHW)
Study: 15205717
Drug: Atorvastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 20 mg per day (n=24)
Study: 11723148
Drug: 125‐mg b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125‐mg b.i.d. doses of levodopa/benserazide (Madopar)
Study: 8267134
Drug: Haloperidol treatment
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol treatment (plasma levels varied, duration 6 weeks)
Study: 17661330
Drug: Echinacea purpurea
Normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea (daily use for at least 7 days)
Study: 11050634
Drug: High-viscosity ferristene
Normalized name: Mineral Oil (high Viscosity)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-viscosity ferristene formulations
Study: 9329701
Drug: Propentofylline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propentofylline (3 x 300 mg taken 1 hr before food)
Study: 3564873
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (0.25%) continuously administered by infusion pump, 4‐6 ml h‐1, for 48 h
Study: 3564873
Drug: Epidural morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine, 2‐6 mg, at the end of operation and repeated on the first and second postoperative mornings
Study: 3564873
Drug: Epidural morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine, 2‐6 mg per die, administered for 48 h continuously by infusion pump
Study: 3564873
Drug: Intramuscular oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxycodone (0.15 mg kg‐1) on request
Study: 25011643
Drug: Thrombin-based topical
Normalized name: thrombin Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin-based topical haemostatic agent (Floseal)
Study: 23442748
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during community screening campaigns.
Study: 23442748
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during campaign 1.
Study: 23442748
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during campaigns 2 and 3.
Study: 23442748
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during campaign 4.
Study: 12671888
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 200 mg
Study: 10846910
Drug: Urapidil (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (0.4 mg/kg)
Study: 8401358
Drug: Propantheline 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propantheline 30 mg orally every 6 h for six doses
Study: 29909565
Drug: Topical pimecrolimus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus, applied four times daily for 4 weeks
Study: 29909565
Drug: Betamethasone cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone cream, applied four times daily for 4 weeks
Study: 27462136
Drug: Alprazolam 0.5
Normalized name: alprazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.5 mg daily for two weeks
Study: 25169639
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for benign struma ovarii (25 cystectomies, 15 unilateral salpingo-oophorectomies, 2 bilateral salpingo-oophorectomies, 22 hysterectomies with salpingo-oophorectomy)
Study: 25169639
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for malignant struma ovarii (1 fertility-sparing staging surgery, 2 unilateral salpingo-oophorectomies, 1 hysterectomy with bilateral salpingo-oophorectomy)
Study: 25169639
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after surgery for malignant struma ovarii (2 patients)
Study: 15753235
Drug: Modafinil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (400 mg x 1)
Study: 6806155
Drug: Intravenous mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mannitol (1 g/kg)
Study: 6806155
Drug: Dexamethasone (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (32 mg stat, 8 mg qds)
Study: 25327872
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of double‐balloon catheter and oral misoprostol
Study: 21067880
Drug: Iodine concentration
Normalized name: iodine Topical Solution [QuarterMate Concentrate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine concentration of 370 mg I/mL (Group B)
Study: 21067880
Drug: Iodine concentration
Normalized name: iodine Topical Solution [QuarterMate Concentrate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine concentration of 300 mg I/mL (Group A)
Study: 19308807
Drug: Add-on intraprostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on intraprostatic BoNT‐A injection (200-600 U of Botox)
Study: 15452006
Drug: Ads incorporating
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ads incorporating a prescription drug benefit box
Study: 15452006
Drug: Ads without
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ads without a prescription drug benefit box
Study: 15452006
Drug: General perception
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: General perception of benefit data in drug ads
Study: 30309327
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection (SMI) 0.6 mL/kg administered intravenously from the time of anesthesia induction to the beginning of CPB.
Study: 21601343
Drug: CRQ-SAS (self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRQ-SAS (self-administered version)
Study: 21601343
Drug: CRQ-IA (interviewer-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRQ-IA (interviewer-administered version)
Study: 18468272
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (BTX‐A)
Study: 16820551
Drug: Acetaminophen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4 g daily)
Study: 1803767
Drug: Live recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live recombinant influenza vaccine
Study: 24855368
Drug: SIMVA 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIMVA 10, 20, or 40 mg
Study: 24855368
Drug: ERN/LRPT 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT 1 g/20 mg + SIMVA (10, 20, or 40 mg)
Study: 18831744
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg (two 40 mg injections at baseline followed by one 40 mg injection every other week from Week 1 to Week 15)
Study: 12944570
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg of everolimus per day
Study: 12944570
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of everolimus per day
Study: 12944570
Drug: Azathioprine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (1.0 to 3.0 mg per kg per day)
Study: 10944065
Drug: Endomysium antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endomysium antibodies
Study: 10944065
Drug: IgA-gluten antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA-gluten antibodies
Study: 10944065
Drug: IgG-gluten antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG-gluten antibodies
Study: 8937483
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (CDDP 16 mg/m2 for 5 days with 5-FU 700 mg/m2/day for 5 days)
Study: 8937483
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (CDDP 80 mg on day 1 with 5-FU 700 mg/m2/day for 5 days)
Study: 8937483
Drug: UFT adjuvant
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT adjuvant chemotherapy (600 mg/day from day 1 to day 14) with CBDCA (350 mg/m2 on day 7)
Study: 1587073
Drug: Fenfluramine plus
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine plus phentermine (60 mg fenfluramine plus 30 mg phentermine)
Study: 1587073
Drug: Fenfluramine plus
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine plus phentermine (continued therapy)
Study: 1587073
Drug: Targeted intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted intermittent therapy
Study: 2858708
Drug: Thymopentin (TP-5)
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (TP-5) 50 mg 3 times a week for 3 consecutive weeks
Study: 29492613
Drug: 0.56 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.56 g/kg alcohol in a vodka and tonic-mixed drink
Study: 29492613
Drug: Placebo (tonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tonic with 4 ml of vodka sprayed on top)
Study: 27869096
Drug: 21-Gy involved-field
Normalized name: FIELD MUSHROOM
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-Gy involved-field radiation therapy (IFRT)
Study: 25086593
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with advice on increasing physical activity and a sham treatment
Study: 20637390
Drug: Phloroglucinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloroglucinol (200 mg) with piroxicam (20 mg)
Study: 20637390
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with piroxicam (20 mg)
Study: 16834644
Drug: Propiverine 15
Normalized name: propiverine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 15 mg three times daily
Study: 16834644
Drug: Propiverine 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 45 mg
Study: 16834644
Drug: Oxybutynin 15
Normalized name: oxyBUTYnin 15 mg/24 hr oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 15 mg
Study: 12907830
Drug: Ferric hydroxide-polymaltose
Normalized name: ferric hydroxide
DrugBank: Ferric hydroxide (DB13423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric hydroxide-polymaltose complex (Ferrum, Vifor, Switzerland) 6 mg/d for 3 months, then 3 mg/kg for 3 months
Study: 12907830
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate complex (FerroSanol, Schwarz, Germany) 6 mg/d for 3 months, then 3 mg/kg for 3 months
Study: 11003764
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (n = 167)
Study: 8975951
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 300 mg orally twice a day
Study: 8975951
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg orally BID
Study: 1477017
Drug: Labetalol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (up to 600 mg daily)
Study: 31324181
Drug: Cornelian cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornelian cherry extract (320 mg/day of anthocyanins) for 12 weeks
Study: 22980596
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy (EIS) using either ethanolamine oleate 5% or N‐butyl cyanoacrylate
Study: 20029189
Drug: Nicergoline (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (15 mg t.i.d.)
Study: 20029189
Drug: Nicergoline (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (15 mg t.i.d.) in patients with bilateral basal ganglia involvement
Study: 20029189
Drug: Nicergoline (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (15 mg t.i.d.) in patients with no or unilateral basal ganglia involvement
Study: 9396885
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (dinoprostone) 3 mg
Study: 8186906
Drug: Almitrine bimesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bimesylate (AB) 50-100 mg/day
Study: 3073869
Drug: 5 MU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU/m2 human lymphoblastoid interferon (Wellferon), three times weekly for 6 months
Study: 29065815
Drug: Bio-oxidative ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-oxidative ozone therapy (OG, n = 20)
Study: 21830011
Drug: Misoprostol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (400 μg vaginal)
Study: 11981594
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day sertraline
Study: 11981594
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day sertraline plus 30 mg/day mianserin
Study: 11981594
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day sertraline
Study: 7876651
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections on day 0
Study: 7876651
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection on day 0 and 14
Study: 7876651
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection on day 0 and 30
Study: 7876651
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection on day 0 and 180
Study: 7876651
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose on day 380
Study: 2197845
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of 400 micrograms octreotide per day
Study: 31129874
Drug: Preventive and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive and interceptive orthodontic treatment needs (P&I Tx need) as assessed by the Index for Preventive and Interceptive Orthodontic Needs (IPION)
Study: 31129874
Drug: IPION scores
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPION scores in the definite treatment need group
Study: 27554812
Drug: Daily pasteurized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pasteurized raw whole egg powder
Study: 25772960
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (divided doses)
Study: 25772960
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily intake of Low Molecular Weight (LMW) iron dextran
Study: 24012983
Drug: Aspiration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration therapy plus lifestyle therapy (n=11)
Study: 24012983
Drug: Lifestyle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle therapy only (n=7)
Study: 24012983
Drug: Aspiration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration therapy (n=10 who completed additional year)
Study: 15101486
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 10 milliliters of lidocaine around the drain tube during removal
Study: 7512583
Drug: Topical retinoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoid AGN 190168
Study: 31520370
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (pantoprazole 80 mg, amoxicillin 2000 mg, clarithromycin 1000 mg, and metronidazole 1000 mg daily in divided doses for 14 days)
Study: 31520370
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (pantoprazole 80 mg, amoxicillin 2000 mg, and clarithromycin 1000 mg daily in divided doses for 14 days)
Study: 29114833
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg) and acetaminophen (1000 mg)
Study: 29114833
Drug: Oxycodone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (5 mg) and acetaminophen (325 mg)
Study: 29114833
Drug: Hydrocodone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone (5 mg) and acetaminophen (300 mg)
Study: 29114833
Drug: Codeine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (30 mg) and acetaminophen (300 mg)
Study: 29114833
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of oxycodone and acetaminophen vs hydrocodone and acetaminophen
Study: 15507095
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SIT) with tree pollen (birch)
Study: 9513073
Drug: Zolpidem, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem, 10 mg, administered continuously
Study: 9513073
Drug: Zolpidem, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem, 10 mg, administered intermittently (five nights zolpidem, two consecutive nights placebo per week)
Study: 8062354
Drug: 60-90 mg
Normalized name: budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60-90 mg amitriptylinoxide (AO)
Study: 8062354
Drug: 50-75 mg
Normalized name: hydrochlorothiazide 50 MG / triamterene 75 MG [Maxzide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-75 mg amitriptyline (AM)
Study: 3123092
Drug: O-desmethyl encainide
Normalized name: 5-o-desmethyl omeprazole
DrugBank: YA-101 (DB18121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-desmethyl encainide (ODE) infusion
Study: 3123092
Drug: 3-methoxy-O-desmethyl encainide
Normalized name: 5-o-desmethyl omeprazole
DrugBank: YA-101 (DB18121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-methoxy-O-desmethyl encainide (3MODE) infusion